切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2021, Vol. 09 ›› Issue (01) : 52 -56. doi: 10.3877/cma.j.issn.2095-5782.2021.01.009

所属专题: 文献

基础研究

猪眼动脉灌注卡铂与洛铂药代动力学及对眼组织损伤的实验研究
姜华1, 刘珍银1, 夏杰军1, 刘佩莹1, 张靖2,()   
  1. 1. 510623 广东广州,广州市妇女儿童医疗中心介入血管瘤科
    2. 510055 广东广州,广东省人民医院介入治疗科
  • 收稿日期:2020-08-14 出版日期:2021-02-25
  • 通信作者: 张靖
  • 基金资助:
    广州市妇女儿童医疗中心青年pilot项目(YIP-2018-015)

Pharmacokinetics and injury to eye tissue of intra-arterial (ophthalmic artery) chemotherapy of carboplatin and lobaplatin in porcine

Hua Jiang1, Zhenyin Liu1, Jiejun Xia1, Peiying Liu1, Jing Zhang2,()   

  1. 1. Department of Interventional Radiology & Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangdong Guangzhou 510623
    2. Department of Interventional Therapy, Guangdong Provincial People's Hospital, Guangdong Guangzhou 510055, China
  • Received:2020-08-14 Published:2021-02-25
  • Corresponding author: Jing Zhang
引用本文:

姜华, 刘珍银, 夏杰军, 刘佩莹, 张靖. 猪眼动脉灌注卡铂与洛铂药代动力学及对眼组织损伤的实验研究[J]. 中华介入放射学电子杂志, 2021, 09(01): 52-56.

Hua Jiang, Zhenyin Liu, Jiejun Xia, Peiying Liu, Jing Zhang. Pharmacokinetics and injury to eye tissue of intra-arterial (ophthalmic artery) chemotherapy of carboplatin and lobaplatin in porcine[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2021, 09(01): 52-56.

目的

拟对西藏小型猪经眼动脉分别灌注卡铂和洛铂,研究其药代动力学以及对猪眼组织的损伤程度。

方法

将10只西藏小型猪平均分为A(卡铂组)、B(洛铂组)两组,将卡铂30 mg或洛铂3 mg分别用5%葡萄糖注射液30 mL稀释后经猪脑膜中动脉灌注至眼动脉。药物灌注后,分别于术后0.5 h、1 h、2 h、2.5 h、3 h、3.5 h以及4 h共7个时间点于股动脉取2 mL血液置入EDTA-抗凝紫头管,离心留取血浆,用于检测样品的药物浓度。采血样结束后处死实验猪,取双侧眼球及视神经组织,10%中性甲醛缓冲液固定后行病理HE染色,观察视网膜细胞、视神经细胞以及血管壁形态、周围炎性细胞浸润情况。

结果

A、B组各一只实验猪因穿刺不成功未完成实验,余8只均完成全程实验。卡铂组和洛铂组血液药物浓度随时间点快速下降,给药后3~4 h血液浓度下降趋于平缓。洛铂组药物浓度曲线起始段较卡铂组"陡"。卡铂组与洛铂组经眼动脉灌注术后两组猪视网膜细胞均形态正常,未见细胞溶解或核固缩;视网膜小动脉血管壁完整、内皮细胞形态正常,周围未见明显炎性细胞浸润。两组视神经细胞形态均未见异常。

结论

经猪眼动脉灌注洛铂与卡铂相比,其药物代谢更快,而且未见眼组织和视神经的损伤。本研究对眼组织损伤未设置时间点和灌注次数的对比,因此还需要进一步的研究。

Objective

To evaluate the pharmacokinetics and injury to eye tissue of intra-arterial-ophthalmic artery chemotherapy of carboplatin and lobaplatin in a normal porcine model.

Methods

Ten Tibetan minipigs were divided into two groups: A (carboplatin) group and B (lobetoplatin) group equally. Each pig received a single dose of either 30 mg of carboplatin (group A) or 3 mg of lobaplatin (group B) by middle meningeal artery injection into the ophthalmic artery. After the drug infusion, 2 ml of blood was taken from the femoral artery and placed in EDTA-anticoagulant purple tube at the time of 0.5 hour, 1 hour, 2 hours, 2.5 hours, 3 hours, 3.5 hours, and 4 hours after operation. The plasma is collected by centrifugation to detect the drug concentration of the sample.After the blood samples were taken, the experimental pigs were sacrificed and the bilateral eyeballs and optic nerve tissues were taken. After 10% neutral formaldehyde buffer was fixed, pathological HE staining was performed to observe the morphological changes of retinal cells and optic nerve cells.

Results

One pig died in each group A and B, and the remaining 8 pigs completed the entire experiment. The blood drug concentrations in the carboplatin group and lobaplatin group rapidly decreased with time, and the blood concentration decreased gradually from 3 hours to 4 hours after administration. The initial phase of the drug concentration curve in the lobaplatin group was "steeper" than the carboplatin group. The retinal cell morphology was normal in both groups after ophthalmic artery instillation, and there was no cell lysis or nuclear pyknosis. The morphology of retinal arteriole endothelial cells was normal. There were no abnormalities in the morphology of the optic nerve cells in both groups.

Conclusions

Compared with carboplatin, the drug metabolism of lobaplatin injected through the middle meningeal artery into the ophthalmic artery of pigs was faster. There was no damage to the eye tissue and optic nerve in both groups. However, there are still deficiencies in this study, so it is still necessary to further research.

图1 实验猪颈外动脉分支动脉供血眼动脉
图2 卡铂组和洛铂组血液药物浓度随时间点快速下降,给药后3~4 h血液浓度下降平缓
表1 A组(卡铂)和B组(洛铂)各时间点(给药结束后)血浆铂的药物浓度(μg/L)
图3 卡铂组:视网膜细胞形态正常(黑箭),视网膜血管内皮形态正常(白箭)
图4 洛铂组:视网膜细胞形态正常(黑箭),视网膜血管内皮形态正常(白箭)
图5 卡铂组:视神经形态正常(黑箭)
图6 洛铂组:视神经形态正常(黑箭)
[1]
Tuncer S, Sencer S, Kebudi R, et al. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: first 4-year experience from a single institution in Turkey[J]. Acta Ophthalmol,2016, 94(7): e644-e651.
[2]
季迅达,李家恺,赵军阳, 等. 眼内晚期视网膜母细胞瘤静脉化学治疗失败后行眼动脉介入化学治疗的疗效观察[J]. 中华眼底病杂志, 2015, 31(6): 556-559.
[3]
张靖,赵军阳,项道满, 等. 经导管眼动脉灌注化疗治疗眼内晚期视网膜母细胞瘤化疗失败患者的价值[J]. 中华放射学杂志, 2014, 48(7): 577-581.
[4]
Eagle RC Jr, Shields CL, Bianciotto C, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma[J]. Arch Ophthalmol, 2011, 129(11): 1416-1421.
[5]
Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds [J]. Arch Ophthalmol, 2011, 129(11): 1399-1406.
[6]
Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results[J]. Br J Ophthalmol, 2012, 96(4): 499-502.
[7]
McKeage MJ. Lobaplatin: a new antitumour platinum drug[J]. Expert Opin Investig Drugs, 2001, 10(1): 119-128.
[8]
朱友余,庞刚,石献忠, 等. 眼动脉及其分支的显微解剖学研究[J]. 解剖与临床, 2005, 10(3): 189-191.
[9]
秦玲,吴巧萍,王天科. 新一代铂类药物洛铂在中国肺癌患者治疗中效果的Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(6): 653-659.
[10]
孙旭,隋东虎,吴小华. 一类抗肿瘤新药洛铂治疗卵巢癌研究进展[J]. 中南药学, 2012, 10(12): 899-902.
[11]
Wu X, Tang P, Li S, et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer[J]. Nature Communications, 2018, 9(1): 832.
[12]
Gietema J, Veldhuis GJ, Guchelaar HJ, et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer[J]. British Journal of Cancer, 1995, 71(6):1302-1307.
[13]
史健,袁志芳,刘伟娜, 等. 国产注射用洛铂在恶性肿瘤患者体内药动学的研究[J]. 中国药学杂志, 2007, 42(24):1888-1891.
[14]
田欣,张振勇,吴丽娜, 等. 洛铂腔内灌注治疗恶性胸腹腔积液的临床观察[J]. 临床肿瘤学杂志, 2013, 18(8): 740-742.
[15]
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chinese Journal of Cancer, 2017, 36(1): 83.
[1] 张谊, 张伟令, 黄东生, 王一卓, 孟雪. 恶性实体瘤继发白血病患儿的诊疗及预后[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(01): 67-73.
[2] 汪沛, 倪蓓君, 元及, 宫为一, 范军. 卡瑞利珠单抗联合卡铂和培美曲塞治疗进展期肺腺癌的疗效及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 511-513.
[3] 宋仲洁, 邢益阳. 卡瑞利珠单抗联合紫杉醇脂质体加卡铂一线治疗NSCLC的临床分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 816-818.
[4] 韩晓婷, 毕国斌, 臧家兰. 培美曲塞联合铂类化疗治疗晚期非小细胞非鳞肺癌临床分析[J]. 中华肺部疾病杂志(电子版), 2021, 14(02): 205-207.
[5] 张睿, 石刚, 杨世华, 苏昊, 周思成, 裴炜, 梁建伟, 刘正, 关旭, 赵志勋, 刘骞, 周志祥, 王锡山, 张景, 周海涛. 洛铂用于结直肠癌术中腹腔灌注化疗的药代动力学研究[J]. 中华结直肠疾病电子杂志, 2020, 09(02): 144-149.
[6] 苏昊, 周海涛, 王锡山, 关旭, 赵志勋, 周志祥, 刘骞, 王鹏, 王雪玮, 包满都拉, 张育荣, 马运宾, 周金涛, 陈怀堽, 刘明, 史薪祥, 梁建伟, 裴炜, 刘正, 姜争, 郑朝旭. 洛铂用于结直肠癌术中腹腔灌洗化疗的近期疗效分析[J]. 中华结直肠疾病电子杂志, 2018, 07(02): 125-129.
[7] 刘雯, 张楠, 张诚玥, 赵军阳, 李莉, 李宁东, 李彬. 视网膜母细胞瘤经眼动脉灌注化学药物治疗与经静脉全身化学药物治疗后摘除眼球的组织病理学特征研究[J]. 中华眼科医学杂志(电子版), 2022, 12(03): 140-145.
[8] 张诚玥, 金眉, 阴捷, 吴荣昌, 刘冬悦, 韩立坡, 王争, 王凤仙, 张楠, 赵军阳, 李莉. 经眼动脉与经静脉化学疗法治疗单眼D期视网膜母细胞瘤的临床研究[J]. 中华眼科医学杂志(电子版), 2021, 11(02): 70-75.
[9] 张敬学, 闫雪静, 武珅, 刘谦. CIZ1基因通过调控MEK-ERK1-2信号通路影响视网膜母细胞瘤细胞增殖和凋亡的实验研究[J]. 中华眼科医学杂志(电子版), 2020, 10(04): 198-205.
[10] 杨恺惟, 虞巍, 宋毅. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床探索[J]. 中华临床医师杂志(电子版), 2023, 17(01): 23-27.
[11] 郑小迪, 甘海润, 蔡建勋, 李露婷, 庞鹏飞, 李冰. PLK3基因Y318H罕见突变促进视网膜母细胞瘤的生长[J]. 中华介入放射学电子杂志, 2023, 11(02): 146-154.
[12] 王亮, 郭磊, 李海波, 刘壮, 宋丹, 李静, 张靖. 经后交通动脉进行眼动脉灌注化疗术治疗儿童视网膜母细胞瘤的多中心经验[J]. 中华介入放射学电子杂志, 2022, 10(04): 414-417.
[13] 夏杰军, 赵军阳, 范若思, 刘珍银, 谭小云, 姜华, 张靖. 经眼动脉灌注化疗治疗视网膜母细胞瘤320例的临床研究[J]. 中华介入放射学电子杂志, 2020, 08(03): 211-215.
[14] 姜华, 夏杰军, 赵军阳, Fairooz, 刘佩莹, 张靖. 视网膜母细胞瘤房水及肿瘤组织的基因组信息分析初探[J]. 中华介入放射学电子杂志, 2020, 08(01): 57-61.
[15] 姜华, 邓海浪, 方倩, 徐文婵, 张靖. 动脉化疗与静脉-动脉联合化疗治疗眼内晚期视网膜母细胞瘤的有效性与安全性[J]. 中华介入放射学电子杂志, 2018, 06(02): 118-123.
阅读次数
全文


摘要